Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Patients enrolled in the CENTAURO-2 phase Ib clinical trial

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Characteristic

n

Percent

Age

  ≥ 50

38

76%

  < 50

12

24%

Sex

 Female

33

66%

 Male

17

34%

Primary tumor sitea

 Breast

11

22%

 Colon

8

16%

 Lung

7

14%

 Ovary

7

14%

 Kidney

3

6%

 Uterus

3

6%

 Soft tissues

3

6%

 Anal canal

2

4%

 Rectum

2

4%

 Others

4

8%

Metastasisb

 Liver

13

27%

 Lung

8

16%

 Bone

6

12%

 Lymph nodes

6

12%

 Suprarenal glands

4

8%

 Soft tissue

2

4%

 Others

9

16%

 Without metastasis

2

4%

Statusc

 PD

37

74%

 SD

13

26%

ECOG PS

 0

8

16%

 1

34

68%

 2

8

16%

Trial vaccinations

 Completedd

41

82%

 No completed

9

18%

  1. Patients were eligible for enrollment after having received available therapy and were no longer responding. ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; SD, stable disease. aat the time of initial diagnosis; bat the time of trial inclusion; cRECIST classification at the time of trial inclusion; d39 patients of the 41 were available for antibody tests and sVEGFR-2 at week thirteen; 38 patients were available for platelet VEGF
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us